中華新聞通訊社/中華時報11月14日曼谷訊（記者袁毅強)摘要： 2025 年 11 月在泰國曼谷舉行的「我們的世界」（We Are the World）全球健康創新峰會，在**「中西醫融合突破，共建健康絲綢之路」的宏大願景下圓滿落幕。會議不僅宣佈成功搭建了全球首個跨學科「共融共建」平臺，彙集了頂尖生物科學、AI 專家與中醫智慧，集中攻關癌症與慢性病協同治療。文章將此官方宣言作為起點，隨後深入分析峰會現場嘉賓關於創新與監管的觀點碰撞，並引入國際監管倫理專家及亞洲 AI 科技界與再生醫學領域**的外部趨勢分析，以揭示在強烈融合願景下，跨國醫療創新所面臨的系統性挑戰。
一、峰會官方介紹與願景：中西醫融合，共建「健康絲綢之路」
2025 年 11 月，為期四天的「我們的世界」全球健康創新峰會在泰國曼谷圓滿落幕。本次峰會以**「以融合之力，回應數千萬家庭的痛楚」為使命緣起，明確宣告了開創未來醫學新紀元**的宏大願景。
使命與背景： 聯合發起人鄭志剛博士在致辭中指出，全球每年數千萬人死於慢性病，世界迫切需要新的答案。峰會旨在透過古老智慧與前沿科技的創造性融合來回應這一挑戰。
核心突破與專家陣容： 峰會核心成就在於搭建了全球首個跨學科的**「共融共建」平臺**。多位擁有累計超千年專業經驗的全球頂級專家齊聚一堂，通過密集的議程，集中攻關癌症的協同治療新路徑與慢性病管理與全民養生新體系兩大核心議題。聯合創辦人 Michael Chin 先生更以親身經歷證實了「融合」為個體生命帶來的奇跡。
全球共識與絲綢之路： 泰國前副總理 Phinij Jarusombat 先生前瞻性地提出，需要建設一條新的**「健康的絲綢之路」**。此宏偉藍圖獲得了包括來自二十多個國家領事、中東 Emaar 集團創辦人等 300 位全球政商學界 VIP 嘉賓的廣泛共鳴，彰顯了共建未來健康體系的強大共識。
行動啟程： 聯合創辦人鄭志剛博士、Michael Chin 與 Josephine Ko 女士共同表示：「行動勝於一切言語。」峰會現場見證了**「中醫藥文化協會」及「俠醫者聯盟」**達成深度戰略合作，標誌著「融合」從理念走向組織化。大會同時宣佈下一屆峰會將於 2027 年在中東舉行。
二、峰會核心觀點碰撞：突破性研究與體制適應的爭議
本次峰會的嘉賓爭議圍繞如何劃定醫療創新與監管的邊界展開：
創新支持者（峰會嘉賓）： 拿督陳革成教授（Dato’ Prof. Dr. Mike Chan）明確主張，當傳統醫學無法再提供希望時，創新療法應該被允許在嚴格監督下嘗試，強調患者有權選擇治療。
學界與監管界（峰會嘉賓）： 泰國前衛生部副部長 Phinij Jarusombat 提出警惕，認為監管與倫理必須同步重視。香港中醫藥大學研究員 王清博士 則指出，實驗性療法若未經批准，應僅限於臨床研究環境，而非市場收費使用。
三、國際監管與倫理的兩極辯論：第三方補充論據（外部參考）
峰會關於醫療創新與監管邊界的爭議，與國際間兩大主流觀點高度吻合。以下是來自國際患者組織、醫學評論者及全球治理專家的外部參考觀點，為峰會核心議題提供了更廣闊的辯證視角。
一、支持「創新與開放監管」的一方（正方論據）
此方主要訴求是加速患者可及性和體系靈活性，強調在無治療方案時，生命時間的緊迫性。
國際患者組織領袖的聲音，如 APARDO 和 Rare Diseases International 的 Durhane Wong-Rieger 博士，從罕病患者視角指出，監管應兼顧安全與可及性。她認為，對於無替代治療選項的患者，應允許在嚴格監督下使用實驗性療法，以避免因程式延誤而錯失機會，強調**「延誤就是傷害」。同時，數位健康專家 Paul Wicks 博士 倡議，創新療法不必等到所有大型試驗完成，應採用數位化工具與患者報告結果（PROs）加速風險評估，支持監管採納「動態證據模式」。此外，多場東南亞罕病峰會的共識亦強調，在嚴格監測機制存在的前提下，應賦予某些晚期患者早期使用實驗性產品的選擇權**。
二、主張「審慎監管與患者保護」的一方（反方論據）
此方主要訴求是保障患者安全和證據的嚴謹性，警惕商業利益在倫理灰色地帶中擴張。
英國醫生、BMJ 評論作者 Margaret McCartney 博士作為證據醫學倡議者，指出任何收費的治療必須有足夠證據。她批評，若商業機構在缺乏有效證據的情況下推廣高價療法，將使脆弱患者群體承擔不必要風險。此外，全球健康治理專家 Ilona Kickbusch 則強調跨國醫療活動必須建立統一倫理與監管框架，警示若缺乏此框架，易產生監管套利（Regulatory Arbitrage），最終將損害患者安全。這一立場也與WHO 和 FDA 的官方立場一致：兩大機構均提醒應避免**「未證實療法的商業化」**，且 FDA 明確規定「同情使用」（Expanded Access）不得商業化收費，僅能收取成本。
四、亞洲 AI 科技界的外部趨勢分析：創新實踐與體制挑戰
峰會的論辯引發了對亞洲 AI 醫療和再生醫學領域實踐的深度反思。來自亞洲不同領域的專家意見，為峰會的核心爭議提供了強有力的外部論證。
1. 科技界的呼籲：AI 速度與動態監管
亞洲科技界普遍認為，現有監管體系已難以跟上 AI 賦能的創新速度。
臺灣科技界代表趨勢： 臺灣長佳智能的 李友錚博士 觀點指出，AI 在精准醫療和藥物研發上的速度與能力已遠超現有審批制度，因此，體制必須做出調整。他強調 AI 的演化正走向**「具身式 AI」（Embodied AI），呼籲監管單位採納「動態監管機制」（dynamic regulation）**，以避免創新被過度延遲。
泰國在地應用趨勢： 泰國 AI 健康先驅 Dr. Supiya Charoensiriwath 博士 的實踐則聚焦於 AI 在公共衛生和預防醫學的在地化落地。同時，泰國企業如 CARIVA 和 Looloo Health 的行動，也體現了 AI 在優化醫院流程和遠程診斷可及性上的巨大價值。
2. 再生醫學的實踐案例：劉保池團隊與 AI 潛力
中國再生醫學案例： 來自上海公共衛生的劉保池博導團隊提供的治療方案，利用患者自身的**自體骨髓幹細胞（ABMI/ABMNCs）**修復受損的肝臟和/或胰腺。此案例體現了再生醫學在修復肝功能和改善糖尿病方面的潛力。
3. 癌症與長壽研究突破：AI 加速新藥與精准治療
精准治療加速： AI 在此處扮演**「精准定位」**的角色，能整合患者的基因數據和病史，加速識別和鎖定新的治療靶點，實現個體化治療方案。
新藥研發優化： 在長壽醫學中，AI 通過模擬和分析大量的化合物結構，加速藥物發現和優化給藥方案，例如預測**雷帕黴素（Rapamycin）**等抗衰老藥物的最低有效劑量，降低研發成本和試驗風險。
五、深度分析：地緣政治與跨國倫理挑戰
跨國醫療的倫理黑洞： 峰會的願景和現實之間存在巨大的監管鴻溝。當創新療法從研究走向商業應用時，特別是針對境外患者，倫理監督和患者保護的界線模糊。若缺乏統一標準，「同情使用」容易被包裝成「付費治療」，使處於弱勢的患者群體暴露於未經充分證實的療法的風險之下。
知情同意的真實性困境： 在跨國醫療中，資訊不對等性被極度放大。患者往往在**「最後希望」的壓力下，難以做出真正的知情同意**（Informed Consent）。監管機構必須擔保，無論在哪里提供治療，患者對風險、費用、替代選項和證據基礎都擁有完整透明的知情權。
地緣政治的影響： 峰會體現了亞洲在生物健康領域的強烈崛起意圖，試圖將香港/亞洲定位為下一代醫療中心。然而，缺乏與西方（如 FDA, EMA）同步的嚴格且統一的監管框架，可能導致亞洲部分地區成為**「監管避風港」（Regulatory Haven）**，這將不利於長期國際合作和創新成果的可信度。
六、結語：邁向倫理共識的轉譯通道
「我們的世界」峰會成功地描繪了一幅中西醫融合、科技賦能的宏偉藍圖。然而，從藍圖到真實世界的實踐，必須穿越監管與倫理的雷區。未來的「健康絲綢之路」要行穩致遠，不僅需要 AI 和再生醫學的技術突破，更需要強大的跨國監管協作機制和對患者自主權與安全的堅定承諾。這場辯論的最終意義，在於找到一條將創新成果倫理化轉譯的通道，確保醫療的進步，真正服務於人類的共同健康福祉。
We Are the World Bangkok 2025: Analysis of Innovation Spectrum, Regulatory Boundaries, and Patient Empowerment International Summit Outcomes
ChinaTimes Nov. 14, 2025, Bangkok（Revision） By YIQIANG YUAN
Summary: The “We Are the World” Global Health Innovation Summit, held in Bangkok in November 2025, concluded under the grand vision of “Achieving Breakthroughs in TCM/Western Medicine Fusion to Build a Healthy Silk Road.” The conference announced the successful establishment of the world’s first interdisciplinary “Co-Creation and Co-Integration” platform, bringing together top bioscience, AI experts, and traditional Chinese medicine (TCM) wisdom to tackle cancer and chronic disease through synergistic treatment. This analysis takes the official declaration as its starting point, moving to an in-depth exploration of the on-site guest debate on innovation and regulation, supplemented by international regulatory ethics experts and external trend analysis from the Asian AI technology and regenerative medicine sectors, revealing the systemic challenges faced by cross-border medical innovation amidst a strong vision of integration.
I. Summit Official Introduction & Vision: TCM/Western Medicine Fusion for a “Healthy Silk Road”
The four-day “We Are the World” Global Health Innovation Summit concluded successfully in Bangkok in November 2025. The summit’s mission was rooted in “Responding to the Suffering of Tens of Millions of Families through the Power of Integration,” clearly declaring a grand vision for pioneering a new era of future medicine.
Mission and Background: Co-Initiator Dr. Adrian Cheng noted in his opening speech that millions globally die annually from chronic diseases, emphasizing the world’s urgent need for a new answer. The summit aimed to address this challenge through the creative fusion of ancient wisdom and cutting-edge technology.
Core Breakthroughs and Expert Lineup: The summit’s core achievement was the establishment of the world’s first interdisciplinary “Co-Creation and Co-Integration” platform. Multiple top global experts with over a thousand years of combined professional experience gathered to focus on two core issues through intensive agendas: Cancer’s Synergistic Treatment Pathways and a New System for Chronic Disease Management and Public Wellness. Co-Founder Michael Chin also affirmed the miracles brought by “integration” to individual lives through his personal experience.
Global Consensus and the Silk Road: Former Thai Deputy Prime Minister Mr. Phinij Jarusombat proactively proposed the need to build a new “Healthy Silk Road.” This vision resonated widely among the 300 VIP guests from global political, business, and academic sectors, including consuls from over twenty countries, signifying a strong consensus for building a future health system.
The Launch of Action: Co-Initiators Dr. Adrian Cheng, Michael Chin, and Josephine Ko jointly stated: “Action speaks louder than words.” The summit witnessed strategic collaborations with the “Association for the Promotion of Chinese Medical Culture” and the “Alliance of Righteous Doctors,” marking the transition of “integration” from a concept to organized action. The next global summit was announced to be held in the Middle East in 2027.
II. Core Summit Debate: The Controversy Over Breakthrough Research and System Adaptation
The debate among the summit’s guests focused on defining the boundaries between medical innovation and regulation:
Innovation Advocates (Summit Guests): Dato’ Prof. Dr. Mike Chan asserted that when conventional medicine can no longer offer hope, innovative therapies should be permitted under strict supervision, emphasizing the patient’s right to choose treatment.
Academia and Regulatory Bodies (Summit Guests): Phinij Jarusombat cautioned that regulation and ethics must be equally prioritized. Dr. Wang Qing, a researcher at a Hong Kong Traditional Chinese Medicine University, stated that experimental therapies, if unapproved, must be restricted exclusively to the clinical research environment, not utilized for commercial, fee-for-service purposes.
III. The International Regulatory and Ethical Divide: Third-Party Supplement (External Reference)
The controversy over innovation and regulatory boundaries at the summit highly aligns with two major international viewpoints. Below are external reference viewpoints from international patient organizations, medical reviewers, and global governance experts, providing a broader, dialectical perspective on the summit’s core issues.
I. Supporting “Innovation and Open Regulation” (Pro-Innovation Arguments)
This side primarily advocates for accelerated patient accessibility and system flexibility, emphasizing the urgency of life when no treatment options are available.
The voice of international patient organization leaders, such as Dr. Durhane Wong-Rieger (APARDO and Rare Diseases International), speaking from the rare disease perspective, noted that regulation should balance safety and accessibility. She argues that for patients with no alternative treatment options, experimental therapies should be permitted under strict supervision to prevent them from missing opportunities due to procedural delays, emphasizing that “delay is harm.” Furthermore, digital health expert Dr. Paul Wicks advocates that innovative therapies need not wait for the completion of all large-scale trials, urging the adoption of digital tools and Patient-Reported Outcomes (PROs) to accelerate risk assessment and supporting the regulatory adoption of a “Dynamic Evidence Model.” Additionally, the consensus from several Southeast Asia Rare Disease Summits emphasizes that under strict monitoring mechanisms, certain late-stage patients should be granted the option for early access to experimental products.
II. Advocating for “Prudent Regulation and Patient Protection” (Pro-Safety Arguments)
This side primarily advocates for patient safety and the rigor of evidence, warning against the expansion of commercial interests in ethical grey areas.
Dr. Margaret McCartney, a UK physician and BMJ review author, as an advocate for evidence-based medicine, stated that any fee-based treatment must be backed by adequate evidence. She criticizes that if commercial entities promote high-cost therapies without sufficient evidence, vulnerable patient groups will assume unnecessary risks. Furthermore, Ilona Kickbusch, a global health governance expert, emphasizes that cross-border medical activities must establish a unified ethical and regulatory framework, warning that a lack thereof can lead to Regulatory Arbitrage, ultimately compromising patient safety. This stance is consistent with the official positions of the WHO and the FDA: both agencies caution against the “commercialization of unproven therapies,” and the FDA explicitly stipulates that “Expanded Access” (compassionate use) cannot be commercially charged, only cost-recovery fees can be collected.
IV. External Analysis of Asian AI Technology Trends: Innovation Practice and System Challenges
The summit’s debate prompted a deeper reflection on practices within the Asian AI healthcare and regenerative medicine sectors. Expert opinions from different Asian regions provide robust external arguments supporting the core controversy.
1. The Technology Sector’s Call: AI Speed and Dynamic Regulation
The Asian technology community generally argues that existing regulatory systems are struggling to keep pace with AI-enabled innovation.
Taiwan Technology Representative Trend: The viewpoint of Dr. Li You-Cheng of Chang Gung AI in Taiwan highlights that AI’s speed and capability in personalized medicine and drug discovery far surpass existing approval systems; therefore, the system must adapt. He emphasized that AI is evolving toward “Embodied AI,” calling for regulatory bodies to adopt a “Dynamic Regulation” mechanism to prevent innovation from being unduly delayed.
Thai Local Application Trend: The work of Thai AI health pioneer Dr. Supiya Charoensiriwath focuses on the localized implementation of AI in public health and preventive medicine. Additionally, the actions of Thai companies like CARIVA and Looloo Health demonstrate the huge value of AI in optimizing hospital workflows and remote diagnosis accessibility.
2. Regenerative Medicine Case Study: Liu Baochi Team and AI Potential
China Regenerative Medicine Case: The treatment approach by Professor Baochi Liu’s team from Shanghai Public Health—utilizing the patient’s own Autologous Bone Marrow Stem Cells (ABMI/ABMNCs) to repair the damaged liver and/or pancreas—provides a specific academic case study of regenerative potential.
Technology Sector Analysis: Technology representatives observed that high-precision regenerative therapies like Professor Liu’s method are highly dependent on AI for processing and predicting complex biological data. AI can optimize the in vitro stem cell differentiation process, predict efficacy, and assist in the precise planning of micro-invasive interventions.
3. Cancer and Longevity Breakthroughs: AI Accelerates New Drugs and Precision
Precision Treatment Acceleration: AI serves as the “precision locator,” integrating patient genomic and historical data to accelerate the identification of new therapeutic targets, enabling individualized treatment plans.
New Drug Development Optimization: In longevity medicine, AI accelerates drug discovery and optimizes dosing regimens by simulating and analyzing compound structures, such as predicting the optimal minimum effective dose for anti-aging drugs like Rapamycin, thereby reducing R&D costs and trial risks.
V. Deep Analysis: Geopolitics and Cross-Border Ethical Challenges
The Ethical Black Hole of Cross-Border Healthcare: A significant regulatory gap exists between the summit’s vision and reality. When innovative therapies move from research to commercial application, especially for foreign patients, the boundary of ethical oversight and patient protection blurs. Without uniform standards, “compassionate use” can easily be disguised as “fee-for-service treatment,” exposing vulnerable patient groups to the risks of insufficiently proven therapies.
The Authenticity Dilemma of Informed Consent: Information asymmetry is highly amplified in cross-border medical care. Patients, often under the pressure of “last hope,” struggle to provide genuine Informed Consent. Regulatory bodies must guarantee that, regardless of where treatment is provided, patients have full and transparent knowledge of the risks, costs, alternative options, and evidence base.
The Impact of Geopolitics: The summit reflects Asia’s strong intention to rise in the biohealth sector, aiming to position Hong Kong/Asia as the next generation’s medical hub. However, a lack of strict and unified regulatory frameworks synchronized with the West (e.g., FDA, EMA) may lead to certain parts of Asia becoming a “Regulatory Haven,” which would be detrimental to long-term international collaboration and the credibility of innovative achievements.
VI. Conclusion: Towards a Translational Pathway of Ethical Consensus
The “We Are the World” Summit successfully painted a magnificent blueprint of TCM-Western medicine integration, technologically empowered. However, the path from blueprint to real-world practice must navigate the minefield of regulation and ethics. For the future “Healthy Silk Road” to proceed stably, it requires not only technological breakthroughs in AI and regenerative medicine but also robust cross-border regulatory collaboration mechanisms and an unwavering commitment to patient autonomy and safety. The ultimate significance of this debate lies in finding a channel to ethically translate innovative achievements, ensuring that medical progress truly serves the common health and well-being of humanity.